Please login to the form below

Not currently logged in
Email:
Password:

Astellas' EMEA president Ken Jones resigns

He will be succeeded by the firm's marketing head Yukio Matsui

Astellas Ken Jones

He joined Yamanouchi as vice president, European marketing, in 2003 ahead of its 2005 merger with Fujisawa to form Astellas, and prior that spent 16 years at Allergan working in Europe, the US and Japan.

Jones' replacement at Astellas will be Yukio Matsui, who currently serves as senior vice president, head of marketing strategy for Astellas' global strategic products.

Yoshihiko Hatanaka, Astellas' president and CEO, said: “The appointment of Yukio Matsui as president of EMEA Operations brings more than 30 years experience to the role - including various important positions in all four regions including Japan, Americas, EMEA, and Asia/Oceania.

“This experience will be crucial in securing the future success of Astellas for all stakeholders and helping the organisation to stay focused on our vision to be on the forefront of healthcare change to turn innovative science into value for patients." 

During his time at Astellas Matsui has held a variety of sales, marketing and strategic planning roles and will start in his new role on 1 April.

He said: "I join at an exciting time with recent launches of a number of innovative medicines and a compelling pipeline in late-stage clinical development for our region.

“With my international business experiences in both developed countries as well as emerging countries and the combined talents of more than 4,700 colleagues across all the functions in the EMEA region, I am confident we will deliver on the Astellas promise of improving the lives of those patients who depend on our medicines."

7th March 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics